New Posts New Posts RSS Feed - New Therapies For Metastatic Disease
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

New Therapies For Metastatic Disease

 Post Reply Post Reply
Author
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 13302
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Topic: New Therapies For Metastatic Disease
    Posted: Mar 15 2011 at 6:28am

New Therapies For Metastatic Disease Addressed In Updated NCCN Guidelines For Breast Cancer


Women with metastatic breast cancer have expanded treatment options for treating the disease and in the prevention of skeletal-related events as outlined in the recently updated NCCN Guidelines™ for Breast Cancer. Robert W. Carlson, MD, of Stanford Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Breast Cancer, presented these and other notable updates to the NCCN Guidelines at the NCCN 16th Annual Conference on March 10, 2011.

"Considering there are limited options for women with metastatic breast cancer who have already received other therapies, this is a noteworthy treatment option that the Panel felt was important to incorporate into the Guidelines"

Eribulin (Halaven™, Eisai Inc.) was added to the NCCN Guidelines as a preferred single agent option in the treatment of metastatic disease, noted Dr. Carlson. Eribulin received FDA approval for the treatment of metastatic breast cancer in patients who received at least two prior chemotherapy regiments for late-stage disease, based on results from a phase 3 study. The study showed that eribulin provided statistically significant overall survival improvements in metastatic breast cancer patients previously treated with an anthracycline and a taxane.

"Considering there are limited options for women with metastatic breast cancer who have already received other therapies, this is a noteworthy treatment option that the Panel felt was important to incorporate into the Guidelines," said Dr. Carlson.

For patients with breast cancer whose disease has metastasized to their bones, the updated NCCN Guidelines now include denosumab (XGEVA™, Amgen) as an option for the prevention of skeletal-related events, such as fractures and bone pain. Denosumab was approved by the FDA following the results of a study comparing denosumab and zoledronic acid (Zometa®, Novartis Oncology) finding denosumab to be at least as efficacious as zoledronic acid in preventing skeletal-related events.

"Skeletal complications as a result of bone metastases can be a major source of pain and significantly decrease the quality of life of a patient with cancer. The weakened bones can lead to fractures and compression of the spinal cord and necessitate procedures like surgery and radiation underscoring the need for additional treatment options," said Dr. Carlson.

http://www.medicalnewstoday.com/articles/218962.php


DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.